Form 4: Sutro Biopharma Director Granted Stock Options

Sutro Biopharma Director Joseph M. Lobacki was granted 1,500 stock options with an exercise price of $10.38, vesting monthly starting January 23, 2026.

Summary

• Joseph M. Lobacki, a Director of Sutro Biopharma, Inc. (STRO), was granted 1,500 stock options.
• The transaction date for this grant was December 23, 2025.
• The exercise price for these stock options is $10.38 per share.
• The options will vest as to 16.67% of the total award monthly, contingent on continued service to the issuer.
• The first tranche of options is scheduled to vest on January 23, 2026.
• The expiration date for these stock options is December 23, 2035.
• Following this transaction, Joseph M. Lobacki beneficially owns 1,500 derivative securities (stock options).
• A Limited Power of Attorney was executed on October 6, 2025, appointing Regina Cheng, David Pauling, and Gregory Chow as attorneys-in-fact to execute SEC Forms 3, 4, and 5 on behalf of Joseph Lobacki.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the option grant aligns director interests with shareholders, which is generally viewed favorably, though it is a routine compensation event.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The stock options are subject to a monthly vesting schedule, with the first tranche vesting on January 23, 2026, indicating a future alignment of the director's incentives with the company's performance over time.

Industry Context

The grant of stock options to a director is a common practice in the biopharmaceutical industry and publicly traded companies generally, serving as a form of equity compensation to attract, retain, and incentivize key personnel.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across the biopharmaceutical industry and public companies, aligning director interests with shareholder value.
• The vesting schedule is typical for equity compensation, promoting long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The grant of 1,500 stock options to Joseph M. Lobacki, a director, constitutes a transaction with a related party. This is a standard form of director compensation and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The option grant aligns the director's long-term interests with shareholder value creation, potentially leading to more focused strategic decisions.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will begin vesting on January 23, 2026, and continue monthly thereafter, subject to the director's continued service.

Key Dates

Recommendation

This Form 4 reports a routine stock option grant to a director as part of their compensation. It does not contain information that would materially alter the company's fundamentals, financial outlook, or strategic direction, thus not warranting a change in investment recommendation based solely on this filing.

Keywords

Sutro Biopharma, STRO, stock option, insider transaction, director compensation, Form 4, equity grant, biopharma